passage-58
abstract
Partial peroxisome proliferator-activated receptor agonist angiotensin receptor blockers. Potential multipronged strategy in stroke prevention.  BACKGROUND AND PURPOSE: Although their primary mechanism of action is blood pressure lowering, emerging data suggest that select angiotensin receptor blockers (ARBs), which partially activate the peroxisome proliferator-activated receptor gamma (PPAR-gamma), may effectively treat insulin resistance and dyslipidemia without the toxicity sometimes associated with full PPAR-gamma agonists. Since up to 50% of the patients with ischemic stroke and transient ischemic attack harbor insulin resistance, drugs that simultaneously control hypertension and insulin resistance could be particularly useful for stroke prevention. SUMMARY OF REVIEW: This review presents the experimental and preliminary clinical evidence supporting a promising role for partial PPAR-gamma agonist ARBs in treating insulin resistance and the metabolic syndrome in patients with ischemic cerebrovascular disease. CONCLUSION: Partial PPAR-gamma agonist ARBs by virtue of their multiple beneficial mechanisms of action could provide a single multipronged strategy for reducing future vascular events in persons with, or at risk for, stroke.
entity-58-0
DISEASE
stroke
entity-58-1
DISEASE
insulin resistance
entity-58-2
DISEASE
dyslipidemia
entity-58-3
DISEASE
ischemic stroke
entity-58-4
DISEASE
transient ischemic attack
entity-58-5
DISEASE
insulin resistance
entity-58-6
DISEASE
hypertension
entity-58-7
DISEASE
insulin resistance
entity-58-8
DISEASE
stroke
entity-58-9
DISEASE
insulin resistance
entity-58-10
DISEASE
metabolic syndrome
entity-58-11
DISEASE
ischemic cerebrovascular disease
entity-58-12
DISEASE
stroke